

## Nomination of Carinne Brouillon (60) as independent director<sup>(1)</sup>

### Education

1990	Institut de Pharmacie Industrielle de Lyon, Lyon, France, Marketing Management
1990	Faculté de Pharmacie de Lyon, Lyon, France, PharmD

### Professional experience

<b>2018-2024</b>	<b>Boehringer Ingelheim, Germany</b>
2020-2024	Head of Human Pharma, Member of the Board of Directors
2018-2020	Head, Global Therapeutic Areas
<b>1997-2018</b>	<b>Janssen (Johnson &amp; Johnson)</b>
2014-2018	Global Commercial Strategy Leader Neuroscience, NJ, USA
2012-2014	President, Janssen Therapeutics, NJ, USA
2010-2012	Managing Director Alpine Cluster (Switzerland & Austria), Switzerland
2009-2009	Managing Director Switzerland, Switzerland
2007-2009	Vice President, Therapeutic Unit, France
2005-2007	Executive Director, CNS Business Unit, France
2003-2005	EMEA Business Director Nephrology & New Business Development, France
2003-2003	European Issues Management Director, France
2000-2002	Chronic Renal Failure Business Unit Director, France
1999-2000	Marketing Director Hospital Business Unit, France
1997-1999	Surgery & Anesthesiology Product Manager, France
<b>1996-1997</b>	<b>FDM Pharma, France, Business Development Manager</b>
<b>1991-1995</b>	<b>bioMerieux, France</b>
1995-1995	Microbiology Marketing Manager
1991-1994	Coagulation Product Manager

### Current Directors mandates

Munich Re (since 2021), Member of the Supervisory Board

### Recommendation of the board of directors

The board of directors formulates a unanimous favourable advice on the candidature of Mrs. Carinne Brouillon as independent director of the Company. Mrs. Carinne Brouillon has the qualifications, skills, knowledge, experience and integrity to make a valuable contribution to the functioning of the board of directors. She committed to make sufficient time available for exercising her mandate. The board confirms that the candidature of Mrs. Carinne Brouillon meets the independence criteria described in article 7:87, §1 of the Companies and Associations Code and principle 3.5 of the 2020 Corporate Governance Code and that it has no indication of anything that might cast doubt on the independence of Mrs. Carinne Brouillon.

(1) For a period of four years ending on the ordinary general meeting of 2029.